ClinicalTrials.gg

Program

relatlimab

Also written as “Relatlimab”, “Nivolumab + Relatlimab” and “relatlimab+nivolumab”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Stomach Neoplasms · Carcinoma, Hepatocellular, led by Bristol-Myers Squibb.

Furthest: phase 4, since Mar 5, 202619 company-led studies, 5 open or runningNext primary completion: May 26, 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb195 open or runningphase 4since Mar 5, 2026Sep 25, 2013May 26, 2029phase 4 · NCT07459543

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Halozyme Therapeutics and Ono Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Sep 25, 2013.

  1. Dec 15, 2016Phase 2 study in Advanced CancerNCT02996110 · 182 enrolled · United States, Australia, Austria and more
  2. Nov 6, 2017Phase 1 study in Advanced CancerNCT03335540 · 20 enrolled · United States
  3. Oct 9, 2018Phase 2 study in Stomach NeoplasmsNCT03704077 · United States, Argentina, Australia and more
  4. Apr 1, 2019Phase 2 study in NeoplasmsNCT03899155 · 1,500 planned · United States, Argentina, Australia and more
  5. Jun 5, 2019Phase 1 study in MelanomaNCT03978611 · 11 enrolled · United States, Belgium, Canada and more
  6. Nov 5, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04623775 · 468 enrolled · United States, Argentina, Australia and more
  7. Aug 4, 2021Phase 3 study in MelanomaNCT05002569 · 1,093 enrolled · United States, Argentina, Australia and more
  8. Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05255601 · 5 enrolled · United States, Australia, France and more
  9. Apr 13, 2022Phase 2 study in Carcinoma, HepatocellularNCT05337137 · 82 enrolled · United States, Australia, Canada and more
  10. Aug 10, 2022Phase 1 study in Advanced Solid TumorsNCT05498480 · 6 enrolled · China
  11. Nov 15, 2022Phase 3 study in MelanomaNCT05625399 · 579 enrolled · United States, Australia, Austria and more
  12. Oct 20, 2023Phase 2 study in MelanomaNCT06101134 · 100 enrolled · United States, Chile, Greece and more
  13. Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386 · 1,000 planned · United States, Argentina, Australia and more
  14. Mar 5, 2026Phase 4 study in MelanomaNCT07459543 · 40 planned · India

Ahead

  1. May 26, 2029Primary completion: phase 4 study in MelanomaNCT07459543
  2. Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155
  3. Jul 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386

TargetBeta

LAG3 →read by rule
“A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), ”NCIt, by rule
“Lymphocyte activation gene 3 protein inhibitor”ChEMBL 37, by rule

Other programs on LAG3

ProgramCompanyFurthest phaseStudies
fianlimabruleRegeneron Pharmaceuticalsphase 310
Anti-PD-1/LAG-3 Bispecific Antibody AK129ruleAkesophase 24
TQB2252Sino Biopharmaceuticalphase 11

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07459543Melanoma · India4Not yet recruitingMay 26, 202940
NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJul 30, 20301,000
NCT06101134Melanoma · United States, Chile, Greece and more2Active, not recruitingApr 10, 2025100
NCT05625399Melanoma · United States, Australia, Austria and more3Active, not recruitingAug 4, 2025579
NCT05498480Advanced Solid Tumors · China1CompletedJan 18, 20246
NCT05337137Carcinoma, Hepatocellular · United States, Australia, Canada and more2CompletedJul 5, 202582
NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more2TerminatedDec 3, 20255
NCT05002569Melanoma · United States, Argentina, Australia and more3TerminatedDec 16, 20241,093
NCT04623775Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2CompletedJan 11, 2024468
NCT03978611Melanoma · United States, Belgium, Canada and more1TerminatedJul 26, 202311
NCT03899155Neoplasms · United States, Argentina, Australia and more2RecruitingAug 25, 20291,500
NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more2WithdrawnFeb 27, 20220
NCT03335540Advanced Cancer · United States1CompletedMar 31, 202120
NCT02996110Advanced Cancer · United States, Australia, Austria and more2CompletedNov 23, 2021182
NCT02966548Neoplasms · Japan1CompletedJul 9, 202435
NCT02935634Advanced Gastric Cancer · United States, Australia, Canada and more2CompletedMay 11, 2022190
NCT02750514Advanced Cancer · United States, Australia, Austria and more2TerminatedJan 29, 2020295
NCT02061761Hematologic Neoplasms · United States, Canada2CompletedFeb 16, 2022106
NCT01968109Neoplasms by Site · United States, Australia, Austria and more2CompletedMay 22, 20241,482

How it is read

Names in the registry

  • “Relatlimab”, 13 entries
  • “Nivolumab + Relatlimab”, 3 entries
  • “relatlimab+nivolumab”, 1 entry
  • “relatlimab+nivolumab+rHuPH20”, 1 entry
  • “Nivolumab + Relatlimab Fixed Dose Combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.